Cyclacel Pharma (CYCC) Misses Q4 EPS by 45c

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($1.18), $0.45 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $277 thousand versus the consensus estimate of $210 thousand.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• UBS says bull market has further to run
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue